PIA
MRNS

Piedmont Investment Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Piedmont Investment Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-158
Closed -$4K – 2425
2018
Q2 		$4K Buy
+158
New +$3.5K ﹤0.01% 2294

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Piedmont Investment Advisors's MRNS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2018, closing a stake of 158 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in MRNS in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 96 funds tracked by Wall St. Rank hold MRNS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 158 Marinus Pharmaceuticals, Inc shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Marinus Pharmaceuticals, Inc position peaked at $4K in Q2 2018.
  • 96 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.